Cardiovascular (CV) morbidity, atherosclerosis, and obesity are all targets of clinical concern and vast research, as is the association between them. Aim of this study is to assess the impact of adipose tissue (including visceral and subcutaneous fat) on abdominal aorta calcification measured on non-enhanced computed tomography (CT). We retrospectively included 492 patients who underwent non-enhanced CT scans during workup for clinically suspected renal colic. All scans were reviewed for abdominal aorta calcification, liver attenuation, and thickness of visceral and subcutaneous fat. Multivariate general linear regression models were used to assess the association between abdominal aorta calcium score and adiposity measures. In the model that included only adiposity measures; visceral fat thickness had statistically significant direct association with abdominal aorta calcium score (B = 67.1, P <.001), whereas subcutaneous pelvic fat thickness had a significant inverse association with abdominal aorta calcium score (B = −22.34, P <.001). Only the association of subcutaneous pelvic fat thickness with abdominal aorta calcium score remained statistically significant when controlling for age, sex, smoking, hypertension, diabetes mellitus, and hyperlipidemia (B = −21.23, P <.001). In this model, the association of visceral fat remained statistically significant in females (B = 84.28, P = .001) but not in males (B = 0.47, P = .973). Visceral fat thickness and subcutaneous pelvic fat thickness were found to have opposing associations with abdominal aorta calcium score. This suggests that while visceral fat may have a lipotoxic effect on aortic atherosclerotic processes, subcutaneous pelvic fat may have a protective role in these processes.

Objective To evaluate the safety and effectiveness of because the failure rate was high in these patients. The remaining 20 patients showed a mean improvehigh-intensity focused ultrasound (HIFU) in patients with benign prostatic hypertrophy (BPH). ments in the AUA symptom score (20.25 to 9.56), Qmax (9.2 to 13.7 mL/s) and QOL score (4.75 to Patients and methods The study comprised 25 patients (mean age 67 years, range 47-84) with BPH treated 2.50). There were no major complications. Conclusions HIFU is safe, produces minimal side-effects using the Sonoblate HIFU device. Patients were evaluated before and after one treatment of HIFU using the or complications and relieves the symptoms of prostatism. American Urological Association (AUA) symptom score, peak urinary flow rate (Qmax) and a qualityKeywords High-intensity focused ultrasound (HIFU), benign prostatic hypertrophy, sonablation, outcome, of-life (QOL) score, and any complications were noted. Results Five patients with large glands were withdrawn symptom score effective in producing instantaneous coagulative necrosis

No abstract